Connect with us

Press Releases

William J. Link, Phd, Named Chairman of Allegro Ophthalmics’ Board of Directors

Executive team strengthened with the sppointment of Stephanie Yee as vice president of finance.




(PRESS RELEASE) SAN JUAN CAPISTRANO, CA — Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel integrin-regulating therapies for the treatment of ocular diseases, announced that William J. Link, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance.

Vicken Karageozian, M.D., president and CEO of Allegro Ophthalmics, said, “I am thrilled that Bill has agreed to serve as our board chairman and pleased to promote Stephanie as VP of finance and member of the executive team. Bill is a pioneer whose vast experience in building and leading successful ophthalmic companies is a tremendous asset at this exciting moment at Allegro. Stephanie has a deep and extensive record in managing the financial operations of a variety of businesses. Their appointments will help to ensure Allegro’s success as we advance our drug candidates—risuteganib for the treatment of intermediate non-exudative age-related macular degeneration (dry AMD) and ALG-1007 for the treatment of dry eye disease—through clinical development.”

Dr. Link is founder and principal of Flying L. Partners and is a founder and managing director of Versant Ventures. Prior to Versant, Dr. Link was a general partner at Brentwood Venture Capital. With more than two decades of operations experience in the healthcare industry, Dr. Link has a proven record of building and managing large, successful medical product companies, including Chiron Vision where he was co-founder, chairman and CEO until it was sold to Bausch + Lomb in 1997. Dr. Link also founded and served as president of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986.

Bringing more than two decades of accounting and finance experience to Allegro, Ms. Yee has held several management roles at ZO Skin Health and ClaripHy Communications, as well as at Emulex Corporation, which was acquired by Avago Technologies and later merged with Broadcom. During her tenure, she became the resident SEC reporting expert and managed due diligence and integration for three acquisitions. Ms. Yee also worked at IntraLase. When IntraLase was acquired by AMO, Ms. Yee coordinated the company’s integration into AMO, now part of Johnson & Johnson.



The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular